Back to Search Start Over

HIF-1α triggers long-lasting glutamate excitotoxicity via system xc− in cerebral ischaemia-reperfusion.

Authors :
Hsieh, Chia‐Hung
Lin, Yu‐Jung
Chen, Wei‐Ling
Huang, Yen‐Chih
Chang, Chi‐Wei
Cheng, Fu‐Chou
Liu, Ren‐Shyan
Shyu, Woei‐Cherng
Source :
Journal of Pathology; Feb2017, Vol. 241 Issue 3, p337-349, 13p
Publication Year :
2017

Abstract

Hypoxia-inducible factor 1α ( HIF-1α) controls many genes involved in physiological and pathological processes. However, its roles in glutamatergic transmission and excitotoxicity are unclear. Here, we proposed that HIF-1α might contribute to glutamate-mediated excitotoxicity during cerebral ischaemia-reperfusion ( CIR) and investigated its molecular mechanism. We showed that an HIF-1α conditional knockout mouse displayed an inhibition in CIR-induced elevation of extracellular glutamate and N-methyl- d-aspartate receptor ( NMDAR) activation. By gene screening for glutamate transporters in cortical cells, we found that HIF-1α mainly regulates the cystine-glutamate transporter (system x<subscript>c</subscript><superscript>−</superscript>) subunit xCT by directly binding to its promoter; xCT and its function are up-regulated in the ischaemic brains of rodents and humans, and the effects lasted for several days. Genetic deletion of xCT in cortical cells of mice inhibits either oxygen glucose deprivation/reoxygenation ( OGDR) or CIR-mediated glutamate excitotoxicity in vitro and in vivo. Pharmaceutical inhibition of system x<subscript>c</subscript><superscript>−</superscript> by a clinically approved anti-cancer drug, sorafenib, improves infarct volume and functional outcome in rodents with CIR and its therapeutic window is at least 3 days. Taken together, these findings reveal that HIF-1α plays a role in CIR-induced glutamate excitotoxicity via the long-lasting activation of system x<subscript>c</subscript><superscript>−</superscript>-dependent glutamate outflow and suggest that system x<subscript>c</subscript><superscript>−</superscript> is a promising therapeutic target with an extended therapeutic window in stroke. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00223417
Volume :
241
Issue :
3
Database :
Complementary Index
Journal :
Journal of Pathology
Publication Type :
Academic Journal
Accession number :
120669402
Full Text :
https://doi.org/10.1002/path.4838